ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2296

Are SDAI50 and DAS28 Response Measures Comparable In Early Rheumatoid Arthritis Patients?

Mohammed Omair1, Edward C. Keystone2, Juan Xiong3, Gilles Boire4, Janet E. Pope5, J. Carter Thorne6, Carol A. Hitchon7, Boulos Haraoui8, Diane Tin9, Deborah Weber3, Vivian P. Bykerk2 and Pooneh Akhavan2, 1Mount Sinai Hospital/University of Toronto, Toronto, ON, Canada, 2Medicine, Mount Sinai Hospital/University of Toronto, Toronto, ON, Canada, 3Mount Sinai Hospital, Toronto, ON, Canada, 4Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, 5St Joseph Health Care, London, ON, Canada, 6Southlake Regional Health Centre, Newmarket, ON, Canada, 7Rheumatology, University of Manitoba, Winnipeg, MB, Canada, 8Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, 9The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Early Rheumatoid Arthritis

  • Tweet
  • Email
  • Print
Session Information

Session Title: Rheumatoid Arthritis-Clinical Aspects III: Outcome Measures, Socioeconomy, Screening, Biomarkers in Rheumatoid Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose: An essential element of treat to target strategy is adjusting therapy in the absence of achieving a target response by 12 wk. A DDAS28 of 1.2 and Simplified Disease Activity Index of 50% (SDAI50) are used as response measures (RM). Our objective was to assess the relationship between the 2 RM and to characterize patients failing to respond based on either RM.

Methods: Data from the Canadian early ArThritis CoHort (CATCH), an early arthritis cohort of patients with symptoms duration of ≤ 12 mo were used. Among patients with RA, we assessed biologic naive patients with available data to calculate DAS28 and SDAI at baseline (BSL) and 12 wk. We included patients on stable DMARD (no D in therapy) during the first 3 mo of f/u. Response to treatment was evaluated at 12 wk.

Correlation and agreement between 2 criteria was assessed by kappa statistics and Spearman correlation. BSL characteristics and median change from BSL were compared in patients with discordant RM. Probability plots of achieving each RM against BSL DAS28 score were evaluated.

Results: In total, 419 patients were included. Most were women (75%) with mean age of 52.6 years. Other BSL variables (mean): disease duration 5.7 months, tender joint count (TJC) 9.0, swollen joint count (SJC) 8.2, DAS28 5.2, SDAI 29.7 and CRP 14.4.

198 (47%) patients failed to achieve a DAS28D and 206 (49%) failed to achieve SDAI50. There was a significant agreement between DAS28 and SDAI50 RM (Kappa 0.66) with a Spearman Correlation of 0.66 (p<0001). Of patients failing SDAI50, 19.2% achieved a DAS28D, of patients failing a DAS28D, 16.6% patients achieved SDAI50. In patients with discordant RM, BSL disease activity measures were higher in DAS28 responders (Table). The probability of achieving the DAS28Dwas higher patients in higher disease activity and it was the opposite in the lower activity range (Figure). Median change of activity measures was higher in patient who achieved DAS28D (Table).

Conclusion: SDAI50 and DAS28 RM are well correlated although in patients in high disease activity states the likelihood of achieving an SDAI50 is lower than achieving a DAS28D, while the reverse is true at lower disease activity states.

Figure: Plot of the predicted probability of achieving criterion DAS1.2 and SDAI50 against baseline DAS28 score.


Table: Comparing baseline characteristics and change in individual disease activity measures from baseline to 3 months in two patients with discordant RM

Baseline variables

Baseline characteristics

Median D in individual activity measures

SDAI50-No  DAS1.2-Yes N=40

SDAI50-Yes   DAS1.2-No  N=32

p-value

SDAI50-No  DAS1.2-Yes N=40

SDAI50-Yes  DAS1.2-No  N=32

p-value

Age (years)*

54.2 ±13.4

52.7 ±16.6

0.507

–

–

–

Female n (%)

29 (73)

27 (71)

0.266

–

–

–

SJC28*

10.3 ± 5.9

4.7 ± 5.26

<.0001

-3.0

-2.0

0.227

TJC28*

12.7 ± 7.0

4.5 ± 5.5

<.0001

-4.0

-2.0

0.012

PHGA*

59.5 ±23.3

38.9 ±26.6

0.002

-20.0

-30.0

0.083

HAQ *

1.2 ± 0.6

0.9 ± 0.7

0.061

-0.44

-0.44

1.000

PTGA*

72.6 ±25.8

36.8 ±27.1

<.0001

-40.0

-10.0

0.005

Pain*

70.7 ±23.6

45.0 ±29.5

<.0001

-40.0

-17.5

0.005

CRP*

23.9 ±20.9

9.3 ±14.5

<.0001

-8.3

-0.3

<0.0001

DAS28*

6.1 ± 1.1

3.8 ± 1.0

<.0001

-1.7

-0.9

<0.0001

SDAI*

38.7 ±14.8

17.6 ±12.2

<.0001

-13.8

-10.7

0.158

*mean (sd)


Disclosure:

M. Omair,
None;

E. C. Keystone,
None;

J. Xiong,
None;

G. Boire,
None;

J. E. Pope,
None;

J. C. Thorne,
None;

C. A. Hitchon,
None;

B. Haraoui,
None;

D. Tin,
None;

D. Weber,
None;

V. P. Bykerk,
None;

P. Akhavan,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/are-sdai50-and-das28-response-measures-comparable-in-early-rheumatoid-arthritis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences